Allspring Global Investments Holdings LLC Buys 934 Shares of Doximity, Inc. (NASDAQ:DOCS)

Allspring Global Investments Holdings LLC raised its position in Doximity, Inc. (NASDAQ:DOCS) by 4.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,754 shares of the company’s stock after buying an additional 934 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Doximity were worth $948,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in DOCS. LRI Investments LLC purchased a new position in shares of Doximity in the first quarter valued at $27,000. Blue Trust Inc. lifted its position in Doximity by 621.4% during the second quarter. Blue Trust Inc. now owns 1,385 shares of the company’s stock valued at $37,000 after purchasing an additional 1,193 shares during the last quarter. GAMMA Investing LLC increased its stake in Doximity by 40.1% in the third quarter. GAMMA Investing LLC now owns 1,439 shares of the company’s stock valued at $63,000 after acquiring an additional 412 shares during the last quarter. Quarry LP increased its position in shares of Doximity by 101.2% during the 2nd quarter. Quarry LP now owns 1,616 shares of the company’s stock valued at $45,000 after purchasing an additional 131,253 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale purchased a new stake in Doximity in the first quarter worth approximately $46,000. 87.19% of the stock is owned by hedge funds and other institutional investors.

Doximity Stock Performance

NASDAQ:DOCS opened at $41.74 on Friday. The firm has a market capitalization of $7.75 billion, a PE ratio of 52.18, a PEG ratio of 5.29 and a beta of 1.29. The stock’s fifty day moving average is $40.55 and its 200 day moving average is $32.21. Doximity, Inc. has a fifty-two week low of $19.89 and a fifty-two week high of $44.88.

Doximity (NASDAQ:DOCS) last released its earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.06. Doximity had a net margin of 32.53% and a return on equity of 19.26%. The firm had revenue of $126.68 million during the quarter, compared to analyst estimates of $119.88 million. Equities analysts forecast that Doximity, Inc. will post 0.8 EPS for the current year.

Insiders Place Their Bets

In other news, Director Watkin Phoebe L. Yang sold 1,011 shares of the company’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $25.54, for a total transaction of $25,820.94. Following the transaction, the director now owns 11,258 shares of the company’s stock, valued at approximately $287,529.32. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Doximity news, Director Watkin Phoebe L. Yang sold 1,011 shares of the firm’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $25.54, for a total transaction of $25,820.94. Following the transaction, the director now directly owns 11,258 shares in the company, valued at $287,529.32. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Anna Bryson sold 30,000 shares of the business’s stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $35.00, for a total transaction of $1,050,000.00. Following the completion of the sale, the chief financial officer now owns 309,627 shares of the company’s stock, valued at approximately $10,836,945. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 37.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Bank of America boosted their target price on Doximity from $32.00 to $45.00 and gave the company a “neutral” rating in a research note on Monday, October 7th. Morgan Stanley lifted their target price on shares of Doximity from $26.00 to $33.00 and gave the company an “underweight” rating in a research note on Wednesday. JPMorgan Chase & Co. upped their price target on Doximity from $27.00 to $30.00 and gave the stock a “neutral” rating in a research note on Monday, August 19th. Canaccord Genuity Group lifted their target price on shares of Doximity from $37.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, August 20th. Finally, Robert W. Baird upped their price target on shares of Doximity from $41.00 to $45.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 17th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $36.42.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.